醇的双重功能使得抗瘤治疗中的线粒体向和氧化还原调节成为可能
Zhiyin Li1, Guorong He1, Zhisheng Liang1
1School of Biomedical and Pharmaceutical Sciences, Guangdong University of Technology, Guangzhou, 510006, China.
European journal of medicinal chemistry
|March 11, 2026
概括
新的醇衍生物向线粒体,以抑制硫素减少酶2 (TrxR2),提供一种更安全,更有效的抗癌策略. 化合物23d显示显著的瘤抑制与最小的毒性.
科学领域:
- 线粒体生物学 线粒体生物学
- 癌症研究 癌症研究
- 药品化学 药品化学 是一个
背景情况:
- 线粒体对于癌细胞的生存至关重要.
- 铁素/铁素还原酶2 (Trx/TrxR2) 系统调节了线粒体中的氧化还原平衡.
- 由于有反应性部分,现有的ent-kaurane类似物存在安全问题.
研究的目的:
- 开发针对线粒体的新型,更安全的ent-kaurane衍生物,用于癌症治疗.
- 为了增强线粒体积累和调节线粒体信号通路.
- 为了研究三酸 (TPP) 结合的酸衍生物的结构-活性关系 (SAR).
主要方法:
- 合成28种TPP结合的醇衍生物.
- 结构与活动关系 (SAR) 分析.
- 在Huh7异种移植的体外和体内疗效研究.
- 涉及线粒体积累,TrxR2抑制,ROS水平和亡诱导的机制研究.
主要成果:
- 在C-13 (TPP) 和C-19 (化) 的双重功能化提高了效能和选择性.
- 结合物23d (C-13 TPP,C-19乙烯) 显示出高强度 (IC50 = 0.19 μM,SI = 15.42).
- 化合物23d有效地抑制了Huh7异种移植的瘤生长,具有良好的安全性.
- 机理学研究证实了线粒体向,TrxR2抑制,ROS升高和ASK1介导的亡.
结论:
- 化合物23d是第一个具有线粒体向性,TrxR2抑制性和体内抗瘤功效的非电友性ent-kaurane衍生物.
- 双重修改策略成功地将生物分布工程与活动优化相结合.
- 这种方法为开发更安全,更有效的抗癌药物提供了一个有希望的途径.
相关概念视频
Electron Transport Chain: Complex I and II
19.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
19.4K
Drugs that Stabilize Microtubules
2.8K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.8K
Targeted Cancer Therapies
9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.1K
Targeted Cancer Therapies
1.7K
1.7K
Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Drugs that Destabilize Microtubules
4.2K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
4.2K


